An apolipoprotein E4 fragment can promote intracellular accumulation of amyloid peptide beta 42

Journal of Neurochemistry

Volumn 115, Issue 4, 2010, Pages 873-884

  Dafnis, Ioannis ^a   Stratikos, Efstratios ^a   Tzinia, Athina ^a   Tsilibary, Effie C ^a   Zannis, Vassilis I ^b,c   Chroni, Angeliki ^a  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

Alzheimer's disease; Amyloid peptide beta; Apolipoprotein E; Apolipoprotein E4 fragments; Intracellular accumulation; Reactive oxygen species

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PEPTIDE BETA 40; AMYLOID PEPTIDE BETA 42; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; APOLIPOPROTEIN E4; BETA SECRETASE; CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PHOSPHATIDYLCHOLINE; REACTIVE OXYGEN METABOLITE; SPHINGOMYELIN; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE FLUIDITY; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; EXTRACELLULAR SPACE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INTRACELLULAR SPACE; NEUROBLASTOMA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN VARIANT;

AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; CELL LINE; CELL LINE, TUMOR; HUMANS; INTRACELLULAR FLUID; PEPTIDE FRAGMENTS; PROTEIN ISOFORMS;

EID: 77958559619     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06756.x     Document Type: Article

References (48)

1. Abramoff M. D., Magelhaes P. J. and Ram S. J. (2004) Image Processing with ImageJ. Biophot. Int. 11, 36-42.
2. Aleshkov S. B., Li X., Lavrentiadou S. N. and Zannis V. I.. (1999) Contribution of cysteine 158, the glycosylation site threonine 194, the amino- and carboxy-terminal domains of apolipoprotein E in the binding to amyloid peptide beta (1-40). Biochemistry 38, 8918-8925.
3. Bae Y. S., Kang S. W., Seo M. S., Baines I. C., Tekle E., Chock P. B. and Rhee S. G. (1997) Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J. Biol. Chem. 272, 217-221.
4. Bandaru V. V., Troncoso J., Wheeler D., Pletnikova O., Wang J., Conant K. and Haughey N. J. (2009) ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. Neurobiol. Aging 30, 591-599.
5. Bayer T. A. and Wirths O. (2008) Review on the APP/PS1KI mouse model: intraneuronal Abeta accumulation triggers axonopathy, neuron loss and working memory impairment. Genes Brain Behav. 7(Suppl 1), 6-11.
6. Bligh E. G. and Dyer W. J. (1959) A rapid method for total lipid extraction and purification. Can. J. Biochem. Physiol. 37, 911-918.
7. Brecht W. J., Harris F. M., Chang S. et al. (2004) Neuron-specific apolipoprotein E4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J. Neurosci. 24, 2527-2534.
8. Burdick D., Kosmoski J., Knauer M. F. and Glabe C. G. (1997) Preferential adsorption, internalization and resistance to degradation of the major isoform of the Alzheimer's amyloid peptide, A beta 1-42, in differentiated PC12 cells. Brain Res. 746, 275-284.
9. Chang S., Ran Ma T., Miranda R. D., Balestra M. E., Mahley R. W. and Huang Y. (2005) Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc. Natl Acad. Sci. USA 102, 18694-18699.
10. Cho H. S., Hyman B. T., Greenberg S. M. and Rebeck G. W. (2001) Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation. J. Neuropathol. Exp. Neurol. 60, 342-349.
11. Chroni A., Pyrpassopoulos S., Thanassoulas A., Nounesis G., Zannis V. I. and Stratikos E. (2008) Biophysical analysis of progressive C-terminal truncations of human apolipoprotein E4: insights into secondary structure and unfolding properties. Biochemistry 47, 9071-9080.
12. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L. and Pericak-Vance M. A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
13. Cutler R. G., Kelly J., Storie K., Pedersen W. A., Tammara A., Hatanpaa K., Troncoso J. C. and Mattson M. P. (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl Acad. Sci. USA 101, 2070-2075.
14. Ditaranto K., Tekirian T. L. and Yang A. J. (2001) Lysosomal membrane damage in soluble Abeta-mediated cell death in Alzheimer's disease. Neurobiol. Dis. 8, 19-31.
15. Galla H. J. and Luisetti J. (1980) Lateral and transversal diffusion and phase transitions in erythrocyte membranes. An excimer fluorescence study. Biochim. Biophys. Acta 596, 108-117.
16. Golabek A. A., Soto C., Vogel T. and Wisniewski T. (1996) The interaction between apolipoprotein E and Alzheimer's amyloid beta-peptide is dependent on beta-peptide conformation. J. Biol. Chem. 271, 10602-10606.
17. Gylys K. H., Fein J. A., Tan A. M. and Cole G. M. (2003) Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-beta protein into synaptic terminals. J. Neurochem. 84, 1442-1451.
18. Haass C. and Selkoe D. J. (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112.
19. Harris F. M., Brecht W. J., Xu Q. et al. (2003) Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc. Natl Acad. Sci. USA 100, 10966-10971.
20. Hashimoto M., Hossain S. and Masumura S. (1999) Effect of aging on plasma membrane fluidity of rat aortic endothelial cells. Exp. Gerontol. 34, 687-698.
21. Huang Y., Liu X. Q., Wyss-Coray T., Brecht W. J., Sanan D. A. and Mahley R. W. (2001) Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc. Natl Acad. Sci. USA 98, 8838-8843.
22. Johnston J. A., Liu W. W., Coulson D. T. et al. (2008) Platelet beta-secretase activity is increased in Alzheimer's disease. Neurobiol. Aging 29, 661-668.
23. Kandimalla K. K., Scott O. G., Fulzele S., Davidson M. W. and Poduslo J. F. (2009) Mechanism of neuronal versus endothelial cell uptake of Alzheimer's disease amyloid beta protein. PLoS ONE 4, e4627.
24. Kang J., Lemaire H. G., Unterbeck A., Salbaum J. M., Masters C. L., Grzeschik K. H., Multhaup G., Beyreuther K. and Muller-Hill B. (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733-736.
25. Kay A. D., Petzold A., Kerr M., Keir G., Thompson E. J. and Nicoll J. A. (2003) Cerebrospinal fluid apolipoprotein E concentration decreases after traumatic brain injury. J. Neurotrauma 20, 243-250.
26. LaFerla F. M., Green K. N. and Oddo S. (2007) Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 8, 499-509.
27. LeBel C. P., Ischiropoulos H. and Bondy S. C. (1992) Evaluation of the probe 2', 7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem. Res. Toxicol. 5, 227-231.
28. Li X., Kypreos K., Zanni E. E. and Zannis V. (2003) Domains of apoE required for binding to apoE receptor 2 and to phospholipids: implications for the functions of apoE in the brain. Biochemistry 42, 10406-10417.
29. Mahley R. W., Weisgraber K. H. and Huang Y. (2006) Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl Acad. Sci. USA 103, 5644-5651.
30. Mason R. P., Jacob R. F., Walter M. F., Mason P. E., Avdulov N. A., Chochina S. V., Igbavboa U. and Wood W. G. (1999) Distribution and fluidizing action of soluble and aggregated amyloid beta-peptide in rat synaptic plasma membranes. J. Biol. Chem. 274, 18801-18807.
31. Mehta P. D., Dalton A. J., Mehta S. P., Kim K. S., Sersen E. A. and Wisniewski H. M. (1998) Increased plasma amyloid beta protein 1-42 levels in Down syndrome. Neurosci. Lett. 241, 13-16.
32. Mehta P. D., Pirttila T., Patrick B. A., Barshatzky M. and Mehta S. P. (2001) Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci. Lett. 304, 102-106.
33. Metzger R. E., LaDu M. J., Pan J. B., Getz G. S., Frail D. E. and Falduto M. T. (1996) Neurons of the human frontal cortex display apolipoprotein E immunoreactivity: implications for Alzheimer's disease. J. Neuropathol. Exp. Neurol. 55, 372-380.
34. Mori K., Yokoyama A., Yang L., Yang L., Maeda N., Mitsuda N. and Tanaka J. (2004) L-serine-mediated release of apolipoprotein E and lipids from microglial cells. Exp. Neurol. 185, 220-231.
35. Myers R. H., Schaefer E. J., Wilson P. W. et al. (1996) Apolipoprotein E4 association with dementia in a population-based study: the Framingham study. Neurology 46, 673-677.
36. Nakamura T., Shoji M., Harigaya Y. et al. (1994) Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease. Ann. Neurol. 36, 903-911.
37. Pillot T., Goethals M., Najib J., Labeur C., Lins L., Chambaz J., Brasseur R., Vandekerckhove J. and Rosseneu M. (1999) Beta-amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: relevance to Alzheimer's disease. J. Neurochem. 72, 230-237.
38. Pitas R. E., Boyles J. K., Lee S. H., Foss D. and Mahley R. W. (1987) Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta 917, 148-161.
39. Saavedra L., Mohamed A., Ma V., Kar S. and De Chaves E. P. (2007) Internalization of beta-amyloid peptide by primary neurons in the absence of apolipoprotein E. J. Biol. Chem. 282, 35722-35732.
40. Smith D. G., Cappai R. and Barnham K. J. (2007) The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim. Biophys. Acta 1768, 1976-1990.
41. Wang L., Han Y., Chen D., Xiao Z., Xi Z., Xiao F. and Wang X. (2010) Cerebrospinal fluid apolipoprotein E concentration decreases after seizure. Seizure 19, 79-83.
42. Waschuk S. A., Elton E. A., Darabie A. A., Fraser P. E. and McLaurin J. A. (2001) Cellular membrane composition defines A beta-lipid interactions. J. Biol. Chem. 276, 33561-33568.
43. Wellnitz S., Friedlein A., Bonanni C., Anquez V., Goepfert F., Loetscher H., Adessi C. and Czech C. (2005) A 13 kDa carboxy-terminal fragment of ApoE stabilizes Abeta hexamers. J. Neurochem. 94, 1351-1360.
44. Wetterau J. R., Aggerbeck L. P., Rall S. C. Jr, and Weisgraber K. H. (1988) Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J. Biol. Chem. 263, 6240-6248.
45. Wilson C., Wardell M. R., Weisgraber K. H., Mahley R. W. and Agard D. A. (1991) Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 252, 1817-1822.
46. Zannis V. I., Kypreos K. E., Chroni A., Kardassis D. and Zanni E. E.. (2004) Lipoproteins and atherogenesis, in Molecular Mechanisms of Atherosclerosis (Loscalzo J., ed.), pp. 111-174. Taylor & Francis, Abington, UK.
47. Zerbinatti C. V., Wahrle S. E., Kim H., Cam J. A., Bales K., Paul S. M., Holtzman D. M. and Bu G. (2006) Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. J. Biol. Chem. 281, 36180-36186.
48. Zhu X., Raina A. K., Lee H. G., Chao M., Nunomura A., Tabaton M., Petersen R. B., Perry G. and Smith M. A. (2003) Oxidative stress and neuronal adaptation in Alzheimer disease: the role of SAPK pathways. Antioxid. Redox Signal. 5, 571-576.